益气解毒方对宫颈癌同步放化疗脾虚型患者治疗效果及对肿瘤标志物的影响  

Therapeutic Effect of Yiqi Jiedu Prescription(益气解毒方)on Cervical Cancer Patients with Spleen Deficiency Undergoing Concurrent Chemoradiotherapy and Its Influence on Tumor Markers

作　　者：吕芸 施晓 孙运明 周海华 谢琼燕 LYU Yun;SHI Xiao;SUN Yunming;ZHOU Haihua;XIE Qiongyan(Zhoushan Women and Children Hospital,Zhoushan 316000,Zhejiang,China)

机构地区：[1]舟山市妇女儿童医院,浙江舟山316000

出　　处：《中华中医药学刊》2023年第9期254-258,共5页Chinese Archives of Traditional Chinese Medicine

基　　金：浙江省医药卫生科技计划项目(2017KY684)。

摘　　要：目的观察益气解毒方对宫颈癌同步放化疗脾虚型患者的治疗效果及其对肿瘤标志物的影响。方法选择2019年12月—2021年12月于舟山市妇女儿童医院进行同步放化疗的72例宫颈癌患者作为研究对象,用随机数表法分成对照组和观察组,对照组进行同步放化疗,观察组在对照组的基础上采用益气解毒方治疗,并随证加减。观察比较两组患者治疗前后的生活质量、肿瘤标志物水平以及不良反应发生情况,评价该方治疗同步放化疗脾虚型患者的质量效果。结果治疗前两组患者的卡氏评分(Karnofsky,KPS)和生活质量评分(quality of life score,QOL)评分无明显差异。与对照组比较,治疗后5周观察组患者的KPS评分和QOL评分明显升高,差异具有统计学意义(P<0.01)。治疗前两组患者的白细胞(white blood cell,WBC)、中性粒细胞(neutrophilic granulocyte,N)、血小板(platelet,PLT)和血红蛋白(hemoglobin,Hb)水平无明显差异。与对照组比较,治疗后5周观察组患者的WBC、N和Hb水平明显升高,差异具有统计学意义(P<0.01);PLT水平有上调趋势,但差异无统计学意义(P>0.05)。治疗前两组患者的鳞状上皮细胞癌抗原(squamous cell carcinoma antigen,SCC-Ag)、癌胚抗原(carcino-embryonic antigen,CEA)、糖类抗原199(carbohydrate antigen,CA199)以及糖类抗原153(carbohydrate antigen,CA153)水平无明显差异。与对照组比较,治疗后5周观察组患者的SCC-Ag、CEA、CA199以及CA153水平明显下降,差异具有统计学意义(P<0.01,P<0.05)。与对照组比较,观察组患者骨髓抑制、泌尿系统反应的发生率明显降低(P<0.01),而胃肠道反应、慢性放射性膀胱炎以及慢性放射性肠炎发生率有下降趋势,但差异不具有统计学意义(P>0.05)。结论益气解毒方能够提高宫颈癌同步放化疗脾虚患者的生活质量,降低肿瘤标志物水平,减轻不良反应,值得应用于临床推广。Objective To observe the therapeutic effect of Yiqi Jiedu Prescription(益气解毒方)on cervical cancer patients with spleen deficiency undergoing concurrent chemoradiotherapy and its effect on tumor markers.Methods A total of 72 cervical cancer patients who received concurrent chemoradiotherapy in Zhoushan Women and Children's Hospital from December 2019 to December 2021 were selected as the study subjects,and were divided into control group and observation group by random number table method.The control group received concurrent chemoradiotherapy,and the observation group received Yiqi Jiedu Prescrip-tion on the basis of the control group and the prescription should be modified according to the syndromes.The quality of life,the levels of tumor markers and the occurrence of adverse reactions were observed and compared between the two groups before and after treatment.The effect was evaluated.Results There was no significant difference in Karnofsky(KPS)or quality of life score(QOL)between the two groups before treatment.Compared with those of the control group,the KPS score and QOL score of the observation group were significantly increased 5 weeks after treatment,and the differences were statistically significant(P<0.01).Before treatment,there were no significant differences in the levels of white blood cell(WBC),neutrophilic granulocyte(N),platelet(PLT)or hemoglobin(Hb)between the two groups.Compared with those of the control group,the levels of WBC,N and Hb of the observation group were significantly increased 5 weeks after treatment,and the differences were statistically sig-nificant(P<0.01).PLT level tended to be up-regulated,but the difference was not statistically significant(P>0.05).The levels of squamous cell carcinoma antigen(SCC-Ag),carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199)and carbohydrate antigen 153(CA153)of the two groups before treatment had no significant differences.Compared with those of the control group,the levels of SCC-Ag,CEA,CA199 and CA153 in the observation group wer

关 键 词：益气解毒方 宫颈癌 同步放化疗 脾虚型 临床效果 肿瘤标志物 

分 类 号：R256.3[医药卫生—中医内科学]